Is American Express a Buy, Sell or Hold?
American Express (NYSE:AXP) holds a notable place in Warren Buffett’s…
Sell
44
PRCT Quote, Financials, Valuation and Earnings
Last price:
$53.05
Seasonality move
:
8.32%
Day range:
$52.13 - $53.19
52-week range:
$47.04 - $103.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.31x
P/B ratio:
7.23x
Volume:
868.4K
Avg. volume:
936.3K
1-year change:
2.39%
Market cap:
$2.9B
Revenue:
$224.5M
EPS (TTM):
-$1.76
Analysts' Opinion
-
Consensus RatingPROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $90.88, PROCEPT BioRobotics has an estimated upside of 71.37% from its current price of $53.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $70.00 representing -- downside risk from its current price of $53.03.
Fair Value
-
According to the consensus of 8 analysts, PROCEPT BioRobotics has 71.37% upside to fair value with a price target of $90.88 per share.
PRCT vs. S&P 500
-
Over the past 5 trading days, PROCEPT BioRobotics has overperformed the S&P 500 by 1.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PROCEPT BioRobotics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PROCEPT BioRobotics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter PROCEPT BioRobotics reported revenues of $68.2M.
Earnings Growth
-
PROCEPT BioRobotics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter PROCEPT BioRobotics reported earnings per share of -$0.35.
Enterprise value:
2.6B
EV / Invested capital:
--
Price / LTM sales:
12.31x
EV / EBIT:
--
EV / Revenue:
11.69x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-25.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$137.1M
Return On Assets:
-22.08%
Net Income Margin (TTM):
-40.72%
Return On Equity:
-31.74%
Return On Invested Capital:
-26.93%
Operating Margin:
-28.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $75M | $136.2M | $224.5M | $43.6M | $68.2M | |
| Gross Profit | $37.1M | $71M | $137.1M | $21.3M | $43.7M | |
| Operating Income | -$80.7M | -$109.2M | -$96.6M | -$29.6M | -$19.7M | |
| EBITDA | -$79.1M | -$98.1M | -$82M | -$25.1M | -$16.4M | |
| Diluted EPS | -$1.96 | -$2.24 | -$1.76 | -$0.54 | -$0.35 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $110.3M | $326.2M | $272.6M | $350.6M | $481.8M | |
| Total Assets | $126M | $337M | $309.3M | $404.7M | $534M | |
| Current Liabilities | $14.5M | $16.2M | $35.3M | $45.9M | $53.1M | |
| Total Liabilities | $308.9M | $69.9M | $112.3M | $124M | $131.8M | |
| Total Equity | -$182.9M | $267.1M | $197.1M | $280.8M | $402.2M | |
| Total Debt | $49M | $50M | $51.2M | $51.3M | $51.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$80.4M | -$108M | -$99.2M | -$24.8M | -$32.4M | |
| Cash From Investing | -$2.7M | -$25.2M | -$4.4M | -$8.7M | -$1.2M | |
| Cash From Financing | $3.6M | $167.8M | $180.1M | $2.9M | $170.5M | |
| Free Cash Flow | -$83M | -$133.2M | -$103.6M | -$33.5M | -$33.6M | |
PRCT
Sector
Market Cap
$2.9B
$35M
Price % of 52-Week High
--
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
2.39%
-41.61%
Beta (5-Year)
--
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$52.35
200-day SMA
Sell
Level
$73.72
Bollinger Bands (100)
Sell
Level
58.32 - 86.64
Chaikin Money Flow
Buy
Level
6.1M
20-day SMA
Sell
Level
$55.72
Relative Strength Index (RSI14)
Sell
Level
42.69
ADX Line
Sell
Level
28.68
Williams %R
Neutral
Level
-50.5167
50-day SMA
Sell
Level
$60.52
MACD (12, 26)
Sell
Level
-2.54
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Sell
Level
-2.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.471)
Buy
CA Score
(Annual)
Level (-0.0707)
Sell
Beneish M-Score
(Annual)
Level (-1.8215)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.0048)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Stock Forecast FAQ
In the current month, PRCT has received 6 Buy ratings 2 Hold ratings, and 0 Sell ratings. The PRCT average analyst price target in the past 3 months is $90.88.
-
Where Will PROCEPT BioRobotics Stock Be In 1 Year?
According to analysts, the consensus estimate is that PROCEPT BioRobotics share price will rise to $90.88 per share over the next 12 months.
-
What Do Analysts Say About PROCEPT BioRobotics?
Analysts are divided on their view about PROCEPT BioRobotics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PROCEPT BioRobotics is a Sell and believe this share price will drop from its current level to $70.00.
-
What Is PROCEPT BioRobotics's Price Target?
The price target for PROCEPT BioRobotics over the next 1-year time period is forecast to be $90.88 according to 8 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is PRCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PROCEPT BioRobotics is a Buy. 6 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PRCT?
You can purchase shares of PROCEPT BioRobotics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PROCEPT BioRobotics shares.
-
What Is The PROCEPT BioRobotics Share Price Today?
PROCEPT BioRobotics was last trading at $53.05 per share. This represents the most recent stock quote for PROCEPT BioRobotics. Yesterday, PROCEPT BioRobotics closed at $53.03 per share.
-
How To Buy PROCEPT BioRobotics Stock Online?
In order to purchase PROCEPT BioRobotics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Baidu Stock a Sleeper AI Winner?
Although the recent policy decisions have gripped the market now,…
JPMorgan Is The Rally Over?
JPMorgan Chase (NYSE:JPM) share price is up 29% over the…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 19
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 19
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 19
Global Payments [GPN] is down 17.44% over the past day.
